From eNewsletter 6/12/2019
DID YOU KNOW that in a new study in Food and Chemical Toxicology, scientists tested lutein against human cervical carcinoma (cancer) cells and found it inhibited proliferation by up to 62.85% after 24 hours and 84.85% after 48 hours of treatment?
Scientists were using very high concentrations of lutein to test for its potential use as chemotherapy. How exciting!
PURE GENOMICS UPDATES
Bonnie & Steve: For those of you who are new to our eNewsletter, the last few years have brought a treasure trove of individualized wellness details thanks to our genetic screening called Pure Genomics.
We can now understand our ability to absorb nutrients, address lifestyle factors affecting our weight and appetite, optimize detoxification pathways for environmental toxins, hormones, and neurotransmitters, target best practices to preserve memory and cognition, improve mood, discover our ideal exercise type to maximize response and prevent injury, ascertain our athletic ceiling, and much more. We are delighted to announce that a new update is available! Gastrointestinal Health One of the most exciting genes in the new Gastrointestinal Health panel is DAO, the enzyme that breaks downs histamine, which is implicit in numerous inflammatory and allergic disorders when it is overproduced. There are multiple natural therapies that can be administered to help produce more DAO enzyme. The other four genes indicate processed meat tolerance, intestinal flora imbalance, H. Pylori risk, and dairy intolerance. Foundation Panel Additions Updates include genes associated with absorption of vitamin D, iron, vitamin E, and vitamin B6. Cognitive Health & Memory Additions Updates now separate the dopamine pathway between memory and addiction risk. A new endocannabinoid gene shows your propensity for THC-cannabis addiction, which is very important given the legalization of cannabis in many states. Those who have a higher risk for addiction are still able to tolerate CBD.
JOINT SUPPLEMENT HELPS THE HEART?
Bonnie & Steve: People who regularly take glucosamine supplements, known for helping mild joint pain and mitigating tissue degradation, appear to have a moderately lower risk for cardiovascular disease (CVD) events.
Results from a recent BMJ study purport that glucosamine use was associated with a 15% lower risk for total CVD events and a 9% to 22% lower risk for stroke, coronary heart disease, and CVD death compared to those not taking it. This recent data aligned with another study, in which high glucosamine use (at least 4 days per week for at least 3 years) was associated with a 17% lower adjusted total mortality risk. The associations can be expl